The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis

Medicine (United States)

Volumn 95, Issue 41, 2016, Pages

  Wang, Huilian ^a,b   Lu, Xi ^b   Yang, Xudong ^a,b   Xu, Nan ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

HIV 1; Nucleotide reverse transcriptase inhibitors; Tenofovir alafenamide; Tenofovir disoproxil fumarate

Indexed keywords

TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GS-7340; TENOFOVIR; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ANTIRETROVIRAL THERAPY; ARTHRALGIA; ARTICLE; BONE DENSITY; COMPARATIVE STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY FUNCTION; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SPINE; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE; VOMITING; ANALOGS AND DERIVATIVES; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; TENOFOVIR; TREATMENT OUTCOME;

EID: 85012005482     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005146     Document Type: Article

References (37)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
3. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26.
4. Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis 2011;53: 1127-9.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 15, 2013.
6. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011;57:773-80.
7. Post FA, Moyle GJ, StellbrinkHJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviralnaive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49-57.
8. VIREAD (Tenofovir Disoproxil Fumarate) Tablets, PowderUS Prescribing Information. Foster City, CA:CGSI; 2012.
9. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir- emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-72.
10. Schafer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency virus infection. Pharmacotherapy 2013;33:665-82.
11. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52: 3144-60.
12. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005;49: 1898-906.
13. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1- (Isopropoxycarbonyl) ethyl]amino]phenoxyphosphinyl]-methoxy] propyl] adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 2008;74:92-100.
14. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15.
15. Mills A, Crofoot GJr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based singletablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2015;69:439-45.
16. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014;67:52-8.
17. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, doubleblind, active-controlled phase 3 trial. Lancet HIV 2016;3:e158-165.
18. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study. Lancet Infect Dis 2016;16:43-52.
19. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, doubleblind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr 2016;72:58-64.
20. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther 2012;17: 1011-20.
21. TungsiripatM, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010;24:1781-4.
22. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(suppl 2):1-85.
23. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120-6.
24. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-72.
25. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011;203:1791-801.
26. Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS 2013;27:2403-11.
27. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1077-82.
28. Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006;62:781-92.
29. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004;39:1199-206.
30. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010;56:872-82.
31. Choi AI, Li Y, Deeks SG, et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010;121:651-8.
32. Wyatt CM, Hoover DR, Shi Q, et al. Microalbuminuria is associated with all-cause and AIDS mortality in womenwith HIV infection. J Acquir Immune Defic Syndr 2010;55:73-7.
33. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012;61:32-40.
34. Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OATdependent cytotoxicity. Antivir Ther 2014;19:687-92.
35. Abraham P, Ramamoorthy H, Isaac B. Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate- induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. J Biomed Sci 2013;20:61.
36. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS 2010;5:524-30.
37. Okparavero AA, Tighiouart H, Krishnasami Z, et al. Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. Antivir Ther 2013;18:793-802.